← Back to Search

Monoclonal Antibodies

Amivantamab for Esophageal Cancer

Phase 2
Recruiting
Led By Steven Maron, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No prior receipt of an EGFR or MET inhibitor for esophagogastric cancer
Adequate organ function: Hemoglobin ≥9 g/dL, ANC ≥1.0 x 10^9 /L, Platelets ≥75 x 10^9 /L, AST and ALT ≤3 x ULN (≤5 x ULN for subjects with liver metastases), Total bilirubin ≤1.5 x ULN, Serum creatinine <1.5 x ULN or creatinine clearance >50 mL/min/1.73 m^2
Must not have
Uncontrolled inter-current illness, poorly controlled diabetes, ongoing or active infection, psychiatric illness/social situation limiting compliance
Recent cardiovascular events (myocardial infarction, unstable angina, stroke, etc.)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

This trial will test amivantamab as a potential treatment for people with EGFR- or MET-amplified esophagogastric cancer. They will look at how effective it is and if it has mild side effects.

Who is the study for?
This trial is for adults with esophagogastric cancer that's spread or can't be removed surgically, who've tried at least one treatment before. They must have specific genetic changes (EGFR or MET amplification) and measurable disease. People with certain heart conditions, other active cancers, uncontrolled illnesses, recent blood clots, liver diseases including hepatitis B or C, lung conditions like ILD, mental health issues affecting trial participation are excluded.Check my eligibility
What is being tested?
Researchers are testing amivantamab to see if it's effective and safe in treating esophagogastric cancer with EGFR or MET gene amplifications. Participants will have had previous treatments and their response to this new drug will be closely monitored.See study design
What are the potential side effects?
While the exact side effects of amivantamab aren't listed here, similar drugs often cause reactions where the drug is injected into the body, skin rashes, fatigue, nausea and potential changes in liver function tests.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have not taken EGFR or MET inhibitors for my esophagogastric cancer.
Select...
My blood counts and liver/kidney functions are within normal ranges.
Select...
My cancer shows EGFR or MET amplification with a high copy number.
Select...
My HER2+ cancer has worsened despite trastuzumab treatment.
Select...
I have esophagogastric cancer that has spread or cannot be removed and have received at least one treatment.
Select...
I am able to get out of my bed or chair and move around.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any major health issues that could interfere with the trial.
Select...
I have not had recent heart attacks or strokes.
Select...
I have severe heart failure or was recently hospitalized for it.
Select...
I do not have any active or chronic liver diseases.
Select...
I have lung disease or a lasting rash from immune therapy.
Select...
I haven't fully recovered from a major surgery before starting treatment.
Select...
I haven't had cancer treatment or recovered from its side effects in the last 2 weeks.
Select...
I have had a recent blood clot in my lungs or veins.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
objective response rate

Trial Design

1Treatment groups
Experimental Treatment
Group I: AmivantamabExperimental Treatment1 Intervention
Patients will receive amivantamab intravenously weekly for the first cycle, and biweekly subsequently at a dose of 1050mg (patients <80kg) or 1400mg (patients ≥80kg). The initial dose will be administered over 2 days in split doses in order to mitigate the risk of infusion reactions. Therapy will continue for up to 2 years or until progression of disease, initiation of alternative cancer therapy, unacceptable toxicity, or other reason to discontinue treatment occurs-whichever comes first.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for esophageal cancer include chemotherapy, radiation therapy, and targeted molecular therapies. Chemotherapy agents like cisplatin and fluorouracil work by damaging the DNA of cancer cells, thereby inhibiting their ability to divide and grow. Radiation therapy uses high-energy rays to kill cancer cells or shrink tumors. Targeted therapies, such as EGFR and MET inhibitors like amivantamab, specifically target and block the activity of proteins involved in cancer cell growth and survival. These targeted treatments are particularly important for esophageal cancer patients with specific genetic mutations, as they can provide a more personalized and effective treatment approach with potentially fewer side effects compared to traditional chemotherapy.
Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,944 Previous Clinical Trials
589,726 Total Patients Enrolled
Janssen PharmaceuticalsIndustry Sponsor
81 Previous Clinical Trials
205,138 Total Patients Enrolled
Steven Maron, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
300 Total Patients Enrolled

Media Library

Amivantamab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05117931 — Phase 2
~8 spots leftby Nov 2025